In conversation with...

Janet Brown on the phase 2/3 STAR trial

February 28, 2023 The Lancet Oncology
In conversation with...
Janet Brown on the phase 2/3 STAR trial
Show Notes

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)